NASDAQ: TLSA - Tiziana Life Sciences Ltd

Lønnsomhet i seks måneder: -21.65%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Tiziana Life Sciences Ltd

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.

flere detaljer
It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2000-03-24
ISIN BMG889121031
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.tizianalifesciences.com
Цена ао 0.426
Prisendring per dag: -3.8% (0.6996)
Prisendring per uke: -13.16% (0.775)
Prisendring per måned: -26.85% (0.92)
Prisendring over 3 måneder: -33.37% (1.01)
Prisendring over seks måneder: -21.65% (0.859)
Prisendring per år: +20.18% (0.56)
Prisendring over 3 år: -30.62% (0.97)
Prisendring over 5 år: -75.75% (2.7751)
Prisendring over 10 år: +0% (0.673)
Prisendring siden begynnelsen av året: -28.78% (0.945)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV 2.91 6
P/E 0 0
EV/EBITDA -2.55 0
Total: 3.25

Effektivitet

Navn Betydning Karakter
ROA, % -145.2 0
ROE, % -319.56 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0161 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % -97.64 0
Lønnsomhet Ebitda, % 29.82 4
Lønnsomhet EPS, % 1356.45 10
Total: 5.4
Flere detaljer

Institusjoner Volum Dele, %
Geode Capital Management, LLC 211167 0.21
HSBC Holdings PLC 164226 0.16
Morgan Stanley 124131 0.12
Ausdal Financial Partners, Inc. 55700 0.05
Zhang Financial LLC 52060 0.05
Ewa, LLC 43476 0.04
UBS Group AG 28559 0.03
Bank of America Corporation 27011 0.03
Barclays PLC 17500 0.02
Cubist Systematic Strategies, LLC 12099 0.01



Veileder Stillingstittel Betaling Fødselsår
Mr. Gabriele Marco Antonio Cerrone M.B.A. Founder, Executive Chairman & Interim CEO 817k 1972 (53 år)
Ms. Keeren Shah Chief Financial Officer 1976 (49 år)
Dr. William A. Clementi Ph.D., Pharm.D. Chief Development Officer
Dr. Napoleone Ferrara M.D. Member of Scientific Advisory Board 1957 (68 år)

Adresse: United Kingdom, London WS XJ, 14/15 Conduit Street - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.tizianalifesciences.com